Since then, several other BCMA‐targeting therapies have been approved for patients with TCE MM in the later‐line setting, including the bispecific antibodies teclistamab [11, 12] and elranatamab [13] and the CAR‐T therapies idecabtagene vicleucel (ide‐cel) [14, 15] and ciltacabtagene autoleucel (cilta‐cel) [16, 17], all of which demonstrated promising outcomes, thus leading to their FDA approval. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.